Anzeige
Mehr »
Login
Donnerstag, 14.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Kolumbiens nächster Kupferriese? Warum Investoren dieses 14.000-Meter-Bohrprogramm beobachten!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
177 Leser
Artikel bewerten:
(1)

CAS and Deloitte China announce a strategic collaboration to empower clients with market insights and scientific innovation expertise

Finanznachrichten News

BEIJING and COLUMBUS, Ohio, Nov. 12, 2024 /PRNewswire/ -- CAS, a division of the American Chemical Society specializing in scientific knowledge management, and Deloitte China, the world's leading professional services organization, have established a strategic collaboration focused on providing end-to-end consulting services ranging from scientific innovation to market strategies.

CAS and Deloitte China announce a strategic collaboration to empower clients with market insights and scientific innovation expertise

CAS and Deloitte China will join forces, enabling clients to accelerate their innovation journey and achieve their business goals, with a focus on the life sciences, new energy, and materials industries. The two organizations signed a strategic cooperation MOU at the China International Import Expo (CIIE).

As a leader in scientific knowledge management, CAS curates, connects, and analyzes science from around the world, building the CAS Content Collection, which covers over 150 years of discoveries. Through scientific information solutions and custom services, CAS empowers customers globally to accelerate their innovation.

Deloitte China helps clients and partners from many sectors seize opportunities, tackle challenges, and attain world-class, high-quality development goals through professional excellence, insight across industries, and intelligent technology solutions.

"We are thrilled to develop and bring to market the industry insight and information solutions trained on CAS content, as a CAS strategic collaborator," said Kevin Guo, Deloitte China National Industry Program Leader. "Scientific technology innovation has demonstrated amazing feats across multiple fields, and I believe that there's a clear need to highlight these achievements. I am excited that in the upcoming months and years, we will witness the outcomes of this collaboration and the significant impact it will have on various industries."

"We are honored to collaborate with Deloitte China," said Manuel Guzman, President, CAS. "Deloitte's market insights prowess coupled with CAS world-class scientific data and technology expertise result in a strong consultative force, which will benefit many organizations by enabling them to accelerate their innovation and achieve their business goals."

As a first step in this collaboration, CAS and Deloitte China will deliver a comprehensive report reviewing the landscape of lithium-ion battery recycling, "Lithium-ion battery recycling: Market and innovation trends for a green future". By integrating CAS data and scientific expertise with Deloitte's market and business analysis, this report will cover everything from policy frameworks and market drivers to the latest research advancements. The formal release of the report is scheduled for early 2025.

About CAS

CAS connects the world's scientific knowledge to accelerate breakthroughs that improve lives. We empower global innovators to efficiently navigate today's complex data landscape and make confident decisions in each phase of the innovation journey. As a specialist in scientific knowledge management, our team builds the largest authoritative collection of human-curated scientific data in the world and provides essential information solutions, services, and expertise. Scientists, patent professionals, and business leaders across industries rely on CAS to help them uncover opportunities, mitigate risks, and unlock shared knowledge so they can get from inspiration to innovation faster. CAS is a division of the American Chemical Society. Connect with us at cas.org.

About Deloitte China

Deloitte China provides integrated professional services, with our long-term commitment to be a leading contributor to China's reform, opening-up and economic development. We are a globally connected and deeply locally-rooted firm, owned by its partners in China. With over 20,000 professionals across 31 Chinese cities, we provide our clients with a one-stop shop offering world-leading audit, tax and consulting services.

We serve with integrity, uphold quality and strive to innovate. With our professional excellence, insight across industries, and intelligent technology solutions, we help clients and partners from many sectors seize opportunities, tackle challenges and attain world-class, high-quality development goals.

The Deloitte brand originated in 1845, and its name in Chinese (??) denotes integrity, diligence and excellence. Deloitte's global professional network of member firms now spans more than 150 countries and territories. Through our mission to make an impact that matters, we help reinforce public trust in capital markets, enable clients to transform and thrive, empower talents to be future-ready, and lead the way toward a stronger economy, a more equitable society and a sustainable world.

Photo - https://mma.prnewswire.com/media/2550750/CAS_and_Deloitte_China_1.jpg
Logo - https://mma.prnewswire.com/media/2550747/CAS_and_Deloitte_Logo.jpg

CAS and Deloitte Logos

Cision View original content:https://www.prnewswire.co.uk/news-releases/cas-and-deloitte-china-announce-a-strategic-collaboration-to-empower-clients-with-market-insights-and-scientific-innovation-expertise-302302764.html

© 2024 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.